Alex Zisson Managing Director & Co-Head of HealthBridge

Alex focuses on investments in the biopharmaceuticals industry, especially in pharmaceuticals, generics, drug delivery and specialty pharma, and biotechnology.

Alex is a Managing Director with H.I.G. HealthBridge Partners. He currently serves on the board of directors for Leiters Health, BioVectra, Orbus Therapeutics, Rising Pharmaceuticals, Navitas, Celerion, Click Therapeutics, and Nevakar. Previous board seats included Arvelle Therapeutics and Taconic Biosciences. Prior to H.I.G., Alex spent 13 years making similar investments at Thomas, McNerney & Partners.

Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. After the merger of Chase H&Q and JPMorgan, Alex became the firm’s healthcare strategist. He was named twice in The Wall Street Journal All-Star Analysts Survey, including his last year at JPMorgan in which he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and ‘home run’ hitting (#8 across all industries).

Alex is the co-chair of the Industry Advisory Board of the Children’s Tumor Foundation, is on the Advisory Board for Brown University’s Medical School, and is on the Life Sciences Council for Springboard Enterprises, a group that assists women in entrepreneurial roles. He is also a board member for the Greenwich Council of the Boy Scouts of America.

He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.